President Donald Trump announced on August 18 that the University of Miami has donated its original 1994 investigational new drug (IND) application for the psychedelic compound ibogaine to the federal government. The move is intended to accelerate research into ibogaine as a potential treatment for serious mental illness, including conditions affecting veterans such as post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression.
The donation was disclosed in a Truth Social post by Trump, who stated that Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. had received the application. Trump framed the gift as a historic step, saying it would provide direct access to foundational FDA authorization to expedite the development of ibogaine as a medical treatment in the U.S.
Federal Response and Policy Context
The announcement follows an April executive order signed by Trump directing federal agencies to speed research and regulatory review of psychedelic-assisted therapies, including ibogaine, psilocybin, MDMA, ketamine, and LSD. The order also allocated approximately $50 million in federal funding for research initiatives and state-level programs studying these treatments for serious mental illness.
The Department of Veterans Affairs (VA) has since expanded its research into psychedelic therapies, including clinical trials involving psilocybin for veterans with treatment-resistant mental health conditions. The VA has emphasized that mental health challenges remain a major concern within the veteran community, with many individuals not responding to conventional medications or psychotherapy.
Mechanisms of the Donation
The 1994 IND application originally filed by the University of Miami represents the foundational regulatory document that enabled early research into ibogaine. By transferring this application to the federal government, the university has effectively streamlined the process for researchers seeking to study or develop ibogaine-based treatments. The move is intended to reduce administrative barriers and accelerate clinical trials.
Trump’s post linked the donation directly to his administration’s broader efforts to address mental health treatment gaps, particularly for veterans. He highlighted anecdotal accounts of ibogaine’s efficacy, citing meetings in the Oval Office with veterans and public figures such as Joe Rogan, who have advocated for psychedelic-assisted therapies.
Scope of Psychedelic Research Under Review
Federal agencies, including the HHS and VA, are currently evaluating multiple psychedelic compounds for their potential therapeutic benefits. The Food and Drug Administration (FDA) has previously designated MDMA and psilocybin as breakthrough therapies for PTSD and depression, respectively, which expedites their development and review processes.
Research into ketamine, already approved for depression in certain formulations, continues to expand, while studies on ibogaine remain in earlier phases due to its classification as a Schedule I controlled substance under federal law. The Drug Enforcement Administration (DEA) has not indicated any immediate changes to ibogaine’s scheduling status as a result of this donation.
Next Steps and Ongoing Challenges
While the donation of the IND application is a concrete administrative step, the timeline for ibogaine’s potential approval as a treatment remains uncertain. Researchers must still conduct rigorous clinical trials to establish safety and efficacy, and regulatory approval will depend on data demonstrating clear benefits over existing therapies.
The VA has indicated that it will continue to prioritize evidence-based treatments while exploring innovative approaches. Veterans’ advocacy groups have expressed cautious optimism about psychedelic therapies but emphasize the need for transparent, peer-reviewed research to ensure patient safety and treatment efficacy.